ISIS 13312

Drug Profile

ISIS 13312

Latest Information Update: 19 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Isis Pharmaceuticals; Novartis Ophthalmics
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 19 Jul 2010 Discontinued - Phase-II for Cytomegalovirus infections in USA (Ophthalmic)
  • 10 Nov 1998 Suspended-II for Cytomegalovirus infections in USA (Ophthalmic)
  • 08 Jan 1998 Phase-I clinical trials for Cytomegalovirus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top